Modeling the Contribution of Synchronous Chemotherapy to the Rate of Grade 3 and 4 Mucositis in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 1, 2009, Pages 315-

  Hartley, Andrew ^a   Sanghera, Paul ^a   Glaholm, John ^a   Fowler, Jack F ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; MITOMYCIN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; HEAD AND NECK CANCER; HUMAN; LETTER; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CONFIDENCE INTERVALS; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; MUCOSITIS; RELATIVE BIOLOGICAL EFFECTIVENESS;

EID: 68649118846     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.007     Document Type: Letter

References (10)

1. Lee IH, Eisbruch A. Mucositis versus tumor control: The therapeutic index of adding chemotherapy to irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. Epub ahead of print March 2009.
2. Kasibhatla M., Kirkpatrick J., and Brizel D. How much radiation is the chemotherapy worth in advanced head and neck cancer?. Int J Radiat Oncol Biol Phys 68 (2007) 1491-1495
3. Fowler J. Correction to Kasibhatla, et-al. How much radiation is the chemotherapy worth in advanced head and neck cancer? (Int J Radiat Oncol Biol Phys 2007;68:1491-1495). Int J Radiat Oncol Biol Phys 71 (2008) 326-329
4. Bentzen S., Ruifrok A., and Thames H. Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: Clinical data on the effect of changing the interval between multiple fractions per day in radiotherapy. Radiother Oncol 38 (1996) 89-101
5. Fu K., Pajak T., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
6. Overgaard J., Hansen H., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet 362 (2003) 933-940
7. Poulsen M.G., Denham J.W., Peters L.J., et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: A Trans-Tasman Radiation Oncology Group Study. Radiother Oncol 60 (2001) 113
8. Bentzen S., Saunders M., Dische S., et al. Radiotherapy-related early morbidity in head and neck cancer: Quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 60 (2001) 123-135
9. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25 (1992) 231-241
10. Bourrhis J., Lapeyre M., Tortochaux J., et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: A GORTEC trial. J Clin Oncol 24 (2006) 2873-2878